News
ANAB
68.85
-1.96%
-1.38
Weekly Report: what happened at ANAB last week (0406-0410)?
Weekly Report · 2d ago
Forte Biosciences: 2026 Is Major Inflection Point For FB102
Seeking Alpha · 4d ago
AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties
Seeking Alpha · 04/08 07:00
Trade Alert: Independent Director Of AnaptysBio John Schmid Has Sold Stock
Simply Wall St · 04/07 18:51
Weekly Report: what happened at ANAB last week (0330-0403)?
Weekly Report · 04/06 10:07
Assessing AnaptysBio (ANAB) Valuation After New Share Buyback Plan And Canceled Equity Offering
Simply Wall St · 04/06 03:19
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)
TipRanks · 04/04 14:50
AnaptysBio files Form 3 for director Susannah Gray, reporting no securities owned
Reuters · 04/03 20:01
Does AnaptysBio’s (ANAB) Buyback-Over-Equity Pivot Redefine Its Capital Discipline Narrative?
Simply Wall St · 04/03 14:31
AnaptysBio director John P. Schmid disposes shares worth $1.1 million
Reuters · 04/02 01:28
AnaptysBio Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/31 16:03
Piper Sandler Maintains Overweight on AnaptysBio, Raises Price Target to $95
Benzinga · 03/31 15:53
Wedbush Remains a Buy on AnaptysBio (ANAB)
TipRanks · 03/31 12:22
AnaptysBio price target raised to $95 from $67 at Piper Sandler
TipRanks · 03/31 10:51
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
Reuters · 03/31 07:39
ANAPTYSBIO INC <ANAB.O>: PIPER SANDLER RAISES TARGET PRICE TO $95 FROM $67
Reuters · 03/31 03:15
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
TipRanks · 03/30 13:05
AnaptysBio Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Dow Jones · 03/30 12:55
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $66 Price Target
Benzinga · 03/30 12:45
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus
Simply Wall St · 03/30 11:11
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it has completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells. Its segments include Biopharma and Royalty Management. Its Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. Its Royalty Management segment manages the financial collaboration for Jemperli from GSK plc and for imsidolimab from Vanda Pharmaceuticals Inc.